Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IA-NANO

Financiado

Albumin particles for intra articular delivery of celecoxib to treat osteoarthri...

Albumin particles for intra articular delivery of celecoxib to treat osteoarthritic inflammation. Osteoarthritis (OA) is the most common chronic condition of the joints and is predicted to become the fourth largest cause of disability in the world by 2020. Its complete mechanism is yet to be deciphered. Though it is not curabl... ver más

31/07/2021

NUID UCD

197K€

Presupuesto del proyecto: 197K€

Líder del proyecto

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-07-31

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100%

2 Participantes

NUID UCD

196.59K€ | Lider

SANYO ESPAÑA

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DesiRTA Localize and Controlled co-delivery of AuNPs conjugated siRN... 200K€ Cerrado

NUEVAS FORMAS DE VEHICULIZACIÓN DE ANTIINFLAM... NUEVAS FORMAS DE VEHICULIZACIÓN DE ANTIINFLAMATORIOS EN CÁPS... 250K€ Cerrado

PRE2018-085973 PEPTIDOS HIBRIDOS PARA EL TRANSPORTE SELECTIVO Y ENTREGA DE... 93K€ Cerrado

NUEVAS FORMAS DE VEHICULIZACIÓN DE ANTIINFLAM... NUEVAS FORMAS DE VEHICULIZACIÓN DE ANTIINFLAMATORIOS EN CÁPS... 10K€ Cerrado

RTI2018-095041-B-C33 SISTEMAS DE LIBERACION DE FARMACOS BASADOS EN POLIMEROS AVAN... 91K€ Cerrado

SAF2017-89890-R PEPTIDOS HIBRIDOS PARA EL TRANSPORTE SELECTIVO Y ENTREGA DE... 145K€ Cerrado

Duración del proyecto: 27 meses Fecha Inicio: 2019-04-11
Fecha Fin: 2021-07-31

Líder del proyecto

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 197K€

Descripción del proyecto Osteoarthritis (OA) is the most common chronic condition of the joints and is predicted to become the fourth largest cause of disability in the world by 2020. Its complete mechanism is yet to be deciphered. Though it is not curable, several medications are prescribed to manage the symptomatic OA, of which the oral and topical medications have shortcomings and the better option is the intra-articular (IA) delivery of free corticosteroids and hyaluronic acid. However, IA delivery is challenging due to the rapid clearance of the free injected molecules from the joint space and outcomes are suboptimal in terms of efficacy and a need for repeated injections. Our objective therefore is to load a candidate drug in a long-acting delivery system and inject it directly into the inflamed knee of a rat model of OA, following in vitro bioassay screening in primary human synoviocytes. Thus, in this project, we propose to develop non-toxic, biocompatible and biodegradable albumin particles loaded with the non-steroidal anti-inflammatory cyclooxygenase-2 inhibitor, celecoxib. This method is expected to reduce the side-effects associated with oral administration of celecoxib. In addition, it will also increase the drug local concentration in the joint and the controlled release of the drug will lead to reduction of inflammatory biomarkers in joints. The project is in line with the EU’s Horizon 2020 Programme focus area - Health, Demographic Change and Wellbeing and UN Sustainable Development goal - Good Health and Well-Being. It will be carried out by the researcher and supervisors who are experts in DDSs development, OA therapy and translational pharmaceutics. Both the researcher and the host are expected to benefit in this collaboration and the researcher will gain experience that will increase her future employability. The project will have great societal impact and commercial potential and will also help increase Europe’s position as the leading source of cutting-edge research.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores